Background: Anti-retroviral treated HIV-infected patients are at risk of mitochondrial toxicity, but non-invasive markers are lacking. Serum FGF-21 (fibroblast growth factor 21) levels correlate strongly with muscle biopsy findings in inherited mitochondrial disorders. We therefore aimed to determine whether serum FGF-21 levels correlate with muscle mitochondrial dysfunction in HIV-infected patients.
Findings
Mitochondrial dysfunction is a well-described complication of anti-retroviral therapy [1] [2] [3] [4] [5] [6] [7] . It is most strongly associated with several of the older nucleoside analogue reverse transcriptase inhibitors (NRTIs): zidovudine (AZT), stavudine (d4T), didanosine (ddI), and zalcitabine (ddC). Although these drugs are no longer in common usage in industrialised countries, there are nevertheless large numbers of patients who have had extensive prior exposure to these drugs, and some remain in common usage in developing countries. We have recently demonstrated that patients with previous exposure to these NRTIs may have persistent cellular mitochondrial COX (cytochrome c oxidase) defects in skeletal muscle, consequent on an NRTI-induced accumulation of somatic (acquired) mitochondrial DNA (mtDNA) mutations [8] .
Non-invasive measures of mitochondrial damage would be very valuable in the HIV clinic, both for the diagnosis of anti-retroviral associated mitochondrial dysfunction and the serial monitoring of such patients. The determination of mtDNA content in peripheral blood mononuclear cells (PBMCs) has previously been proposed as such a measure [5, [9] [10] [11] . This consideration arises from the fact that the mitochondrially-toxic NRTIs (as listed above) cause a reduction in cellular mtDNA content (depletion) during therapy [2, 3, 6, 10, [12] [13] [14] [15] [16] . However, modern N(t) RTIs such as tenofovir (TDF) and abacavir (ABC) do not cause mtDNA depletion [17] , and as a result, mtDNA levels return to normal with a switch away from a mitochondrially-toxic NRTI. Thus, measuring mtDNA levels is not a useful measure of on-going mitochondrial dysfunction due to an NRTI exposure in the distant past.
In contrast, FGF-21 (fibroblast growth factor 21) has recently been proposed as a valuable serum measure in inherited mitochondrial disease [18] . In these patients, serum FGF-21 levels showed a very strong correlation with mitochondrial dysfunction on skeletal muscle biopsy, as determined by the percentage of cells expressing a COX defect [18] . FGF-21 is thought to regulate mitochondrial activity and enhance oxidative capacity, mediated via PGC-1α (peroxisome proliferator-activated receptor gamma co-activator 1-alpha) expression [19] . To date, one study has assessed serum FGF-21 in HIV infection, and demonstrated elevated levels [20] . Given the recently described association between serum FGF-21 elevation and muscle COX defects in inherited mitochondrial disorders [18] , and the recent observation of significant COX defects in long-term anti-retroviral treated HIV-infected patients [8] , we speculated that muscle mitochondrial dysfunction might also drive the FGF-21 elevation in anti-retroviral treated HIV infection.
Patient characteristics
All subjects gave informed written consent for participation, and the study was approved by local research ethics committee (Newcastle and North Tyneside Research Ethics Committee). We performed a crosssectional study of adult HIV-1 infected patients, receiving ambulatory care at one of two specialist clinics in Newcastle-upon-Tyne, UK. Patients with current active hepatitis B or C co-infection, known inherited or non-HIV-associated neuromuscular disease, and diabetes mellitus were excluded. No subjects were clinically obese (BMI >30). 32 HIV-infected subjects participated, of whom 81% were male. 84% were of white Caucasian ethnicity and the remainder black African. Mean age was 48.7 years, with age range of 29-71 years. Mean duration of diagnosed HIV infection was 10.8 years. Mean current CD4 lymphocyte count was 663 cells/μl, and 61% of subjects had nadir CD4 count of <200 cells/ μl. All subjects were currently receiving combination anti-retroviral therapy, with a mean duration of treatment of 9.2 years. 97% of patients had fully suppressed HIV plasma viral load (<50 HIV-1 RNA copies/ml). 81% of subjects were receiving a non-nucleoside reverse transcriptase inhibitor (NNRTI) and 22% a ritonavirboosted protease inhibitor (PI). Regarding past (lifetime) NRTI treatment experience, 72% of patients had a history of AZT exposure, and 25% had a history of prior d-drug (dideoxynucleoside analogue) exposure. Characteristics of individual subjects are shown in Table 1 .
FGF-21 determination
Serum FGF-21 levels were determined by quantitative ELISA (BioVendor, Brno, Czech Republic), performed in triplicate, and normalised by log 10 transformation. A serum FGF-21 level of <200 pg/ml was considered as normal in keeping with recent data [18] . Statistical analyses were performed in SPSS 19, using student's t-test to compare binary variables and Pearson's correlation coefficient (r) to examine the relationship between log 10 serum FGF-21 levels and continuous variables. Twentyone of 32 subjects (66%) had serum FGF-21 levels greater than the normal range, with four being very elevated (>800 pg/ml). On univariate analysis, serum FGF-21 levels were positively correlated with current CD4 lymphocyte count (r = 0.36, p = 0.042), but more strongly correlated with total CD4 cell count gain since initiation of anti-retroviral therapy (current minus nadir) (r = 0.45, p = 0.016) ( Figure 1 ). In addition, plasma glucose levels correlated with serum FGF-21 levels, although this did not quite reach statistical significance (r = 0.34, p = 0.06, Figure 2 ), whereas as serum lipids and liver function did not. No other demographic or treatment variables were significantly associated with serum FGF-21 levels, including the nature of current or prior anti-retroviral therapy (Table 2) . FGF-21 levels did not differ significantly between patients with or without clinical lipodystrophy syndrome. Only CD4 lymphocyte count gain was independently associated with serum FGF-21 levels on multivariate linear regression analysis (p = 0.016).
Skeletal muscle mitochondrial histochemistry
COX histochemistry was performed on cryo-sections obtained from lower limb skeletal muscle biopsies on 31 of the 32 subjects (biopsy data for one subject was not analysable). Results of 22 of these biopsies have been reported in our previous work [8] , whereas the remaining 9 have not. COX contains respiratory chain subunits encoded by the mitochondrial genome, and fibres stain brown (positive) in the presence of intact respiratory chain activity (Figure 3 ). Proportional COX defect was determined by counting ≥500 fibres per biopsy, and normalised by log 10 transformation. There was no correlation between serum FGF-21 levels and percentage COX defects on biopsy (r = −0.02, p = 0.9, Figure 4 ).
Discussion
We have shown that serum FGF-21 levels are frequently elevated in contemporary anti-retroviral treated HIVinfected patients, but do not correlate with the severity of muscle mitochondrial (COX) defect. In contrast, a previous study has shown a very strong correlation between these parameters in patients with inherited mitochondrial disorders [18] . Ours is the first study to attempt to link serum FGF-21 levels with biopsyproven mitochondrial defects in HIV-infected patients. What is the reason for this apparent discrepancy in findings? Firstly, the prior study demonstrating serum FGF-21 elevation in mitochondrial disease included a large number of patients with childhood-onset disease. Such patients typically have very severe muscle COX defects (affecting up to~60% of fibres). In contrast, patients with late-onset inherited mitochondrial disorders typically have more modest COX defects, comparable with those seen in our HIV-infected patients (up to~10% of fibres). The fact that some patients in our study with a biopsy COX defect of >5% of fibres had relatively normal FGF-21 levels suggests that this serum measure is not particularly sensitive for mild to moderate muscle mitochondrial defects. Secondly, the markedly abnormal serum FGF-21 levels seen in some patients with no significant COX defect suggest a nonmitochondrial origin, as has been observed in other metabolic disorders [21] [22] [23] . In the only previous study of FGF-21 levels in HIV infection, the authors found associations of FGF-21 levels with obesity, glycaemia, dyslipidaemia and liver dysfunction, in line with literature from HIV-uninfected patients [24] . In our study, we specifically excluded diabetic and obese subjects (as we wished to maximise the likelihood of detecting any association with NRTI-induced mitochondrial dysfunction). Interestingly however, the strongest predictor of serum FGF-21 levels seen in our study was a novel association with total CD4 lymphocyte count gain. This is an intriguing finding. It is plausible that patients who have low nadir CD4 lymphocyte counts may experience more profound metabolic changes as they undergo immune reconstitution on anti-retroviral therapy, switching from a catabolic state to an excessively anabolic state associated with a 'return to health'. This association with CD4 count gain should be further explored by longitudinal study.
In conclusion, serum FGF-21 levels do not appear to be a sensitive or specific marker of muscle mitochondrial dysfunction in contemporary anti-retroviral treated patients. Nevertheless they are commonly elevated in association with immune recovery. As serum FGF-21 levels in the HIV-uninfected population are elevated in conditions associated with increased cardiovascular risk, it is very plausible that serum FGF-21 elevation in anti-retroviral treated HIV infection may also be a marker of an adverse metabolic risk in this patient group. Given the known increase in cardiovascular disease in anti-retroviral treated patients [25] , the prognostic significance of our findings merits further research. 
